<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Antagonistic Cell Fate Regulation Theory - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-10</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-10</p>
                <p><strong>Name:</strong> Antagonistic Cell Fate Regulation Theory</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why the propensity to get certain cancers is inversely correlated with neurodegenerative disease, based on the following results.</p>
                <p><strong>Description:</strong> The inverse correlation between neurodegenerative diseases and most cancers arises from systemic differences in the regulation of fundamental cell fate decision pathways. Individuals with molecular profiles that favor cell survival, proliferation, and resistance to apoptosis are protected against neurodegeneration but predisposed to cancer, while those with profiles favoring cell death, growth arrest, and apoptosis are protected against cancer but vulnerable to neurodegeneration. This theory posits that shared molecular regulators (p53, PIN1, cell cycle proteins, proteostasis machinery) act as 'cell fate rheostats' whose set-points determine disease susceptibility in opposite directions across tissue types.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Cell Fate Rheostat Principle</h3>
            <p><strong>Statement:</strong> Systemic molecular regulators of cell survival versus death (including p53, PIN1, CDKN2A/p16, and BCL2 family members) establish individual-specific set-points that determine tissue-level propensities: higher tumor-suppressor activity and pro-apoptotic signaling reduce cancer risk while increasing neurodegeneration risk, whereas lower tumor-suppressor activity and enhanced survival signaling increase cancer risk while protecting against neurodegeneration.</p>
            <p><strong>Domain/Scope:</strong> Applies to age-related neurodegenerative diseases (Alzheimer's disease, Parkinson's disease) and most solid cancers in adults, excluding familial/monogenic forms, pediatric cancers, and specific exceptions like melanoma-PD associations. Most applicable to smoking-related cancers and non-melanoma skin cancers where inverse associations are strongest.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Melanoma shows positive association with Parkinson's disease, possibly due to shared melanocytic/dopaminergic biology and alpha-synuclein expression</li>
                <li>Vascular dementia does not show inverse cancer association, indicating specificity to protein-aggregation neurodegenerative diseases</li>
                <li>Liver cancer associated with viral hepatitis shows positive correlation with PD, likely due to virus-induced neuroinflammation</li>
                <li>Effect sizes vary by cancer type, with strongest inverse correlations for smoking-related cancers and skin cancers</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>AD patients had 61% lower risk of any cancer (HR 0.39, 95% CI 0.26-0.58) in Framingham nested case-control; survivors of smoking-related cancers had 74% lower risk of AD (HR 0.26, 95% CI 0.08-0.82) <a href="../results/extraction-result-48.html#e48.0" class="evidence-link">[e48.0]</a> </li>
    <li>PD mortality inversely correlates with colorectal cancer (r_s = -0.39, P < 0.001; OR 0.25) and pancreatic cancer (r_s = -0.40, P < 0.001; OR 0.21) at country level <a href="../results/extraction-result-32.html#e32.0" class="evidence-link">[e32.0]</a> <a href="../results/extraction-result-32.html#e32.1" class="evidence-link">[e32.1]</a> </li>
    <li>Meta-analysis of 107,598 PD patients showed overall cancer RR 0.73, smoking-related cancers RR 0.61, non-smoking RR 0.80 <a href="../results/extraction-result-48.html#e48.1" class="evidence-link">[e48.1]</a> </li>
    <li>NMSC associated with 79% reduced risk of developing AD as sole diagnosis (HR 0.21, 95% CI 0.051-0.87, p=0.031) in Einstein Aging Study <a href="../results/extraction-result-40.html#e40.0" class="evidence-link">[e40.0]</a> </li>
    <li>p53 is upregulated in AD/PD/HD brains promoting neuronal apoptosis, but p53 is mutated/downregulated in most cancers allowing proliferation <a href="../results/extraction-result-49.html#e49.3" class="evidence-link">[e49.3]</a> <a href="../results/extraction-result-37.html#e37.1" class="evidence-link">[e37.1]</a> <a href="../results/extraction-result-45.html#e45.0" class="evidence-link">[e45.0]</a> </li>
    <li>PIN1 is downregulated/oxidatively inactivated in AD hippocampus but overexpressed in many cancers; PIN1 knockout mice develop neurodegeneration but resist tumorigenesis <a href="../results/extraction-result-36.html#e36.0" class="evidence-link">[e36.0]</a> <a href="../results/extraction-result-49.html#e49.4" class="evidence-link">[e49.4]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> While the opposing regulation concept exists, the explicit formalization of shared regulators as individual-specific set-points creating bidirectional vulnerability with defined scope and exceptions represents a novel synthesis of existing observations into a testable systems-level framework.</p>            <p><strong>What Already Exists:</strong> The general concept that apoptosis versus proliferation pathways are oppositely regulated in neurodegeneration and cancer has been proposed (Driver et al. 2012, Roe et al. 2005), with p53 and cell cycle regulators identified as shared factors.</p>            <p><strong>What is Novel:</strong> This statement formalizes the 'rheostat' principle as a unified framework explaining how individual-specific set-points in shared regulators determine bidirectional disease risk, integrating multiple molecular players (p53, PIN1, BCL2, CDKN2A) into a coherent systems-level model with explicit disease scope and quantified effect sizes.</p>
        <p><strong>References:</strong> <ul>
    <li>Driver et al. (2012) Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study [Proposed opposing cell fate pathways as mechanism]</li>
    <li>Roe et al. (2005, 2010) Studies showing bidirectional inverse association [Early epidemiological evidence]</li>
    <li>Lu et al. (2015) Pin1 dysregulation helps to explain the inverse association [PIN1 as specific molecular mediator]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Proteostasis Capacity Divergence</h3>
            <p><strong>Statement:</strong> Protein homeostasis (proteostasis) systems including the ubiquitin-proteasome system (UPS), autophagy, and molecular chaperones are regulated in opposite directions in cancer versus neurodegeneration: cancer cells upregulate proteostasis capacity to support rapid proliferation and handle high protein turnover, while neurodegeneration involves proteostasis decline leading to toxic protein aggregation (Aβ, tau, α-synuclein). This divergence produces opposing disease susceptibilities.</p>
            <p><strong>Domain/Scope:</strong> Applies to protein-aggregation neurodegenerative diseases (AD with Aβ/tau, PD with α-synuclein, HD with huntingtin) and proliferative cancers that depend on enhanced proteostasis. Most relevant to sporadic/age-related forms where proteostasis decline is gradual.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some PD-associated genes (PARK2/Parkin, PINK1) have tumor-suppressive functions when lost in dividing cells but cause neurodegeneration when mutated in neurons</li>
                <li>AT-1/SLC33A1 haploinsufficiency causes both neurodegeneration and cancer propensity in pathogen-exposed mice, showing environmental modulation</li>
                <li>Context-dependent effects: DJ-1/PARK7 loss causes PD but DJ-1 overexpression is oncogenic in gliomas</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Transcriptomic meta-analysis shows ubiquitin-proteasome system consistently downregulated in CNS disorders (AD, PD, schizophrenia) and upregulated in cancers (lung, colorectal, prostate) across KEGG, Reactome, and Biocarta databases <a href="../results/extraction-result-47.html#e47.0" class="evidence-link">[e47.0]</a> <a href="../results/extraction-result-47.html#e47.4" class="evidence-link">[e47.4]</a> </li>
    <li>74 genes downregulated in CNS disorders and upregulated in cancers include proteasome components (PSMD8), aminoacyl-tRNA synthetases (IARS, FARSA), and metabolic enzymes supporting protein synthesis <a href="../results/extraction-result-47.html#e47.3" class="evidence-link">[e47.3]</a> </li>
    <li>Cancer cells upregulate heat-shock proteins (Hsp90, Hsp70) and proteasome activity to support proliferation, while AD shows decreased proteostasis and accumulation of Aβ/tau aggregates <a href="../results/extraction-result-35.html#e35.0" class="evidence-link">[e35.0]</a> <a href="../results/extraction-result-43.html#e43.3" class="evidence-link">[e43.3]</a> </li>
    <li>AT-1 (SLC33A1) S113R haploinsufficiency causes aberrant ER autophagy and neurodegeneration; in pathogen-exposed conditions also causes inflammation-driven cancer (55.5% of dead mutants had cancer) <a href="../results/extraction-result-150.html#e150.0" class="evidence-link">[e150.0]</a> </li>
    <li>PARK2 (Parkin) germline loss causes PD via impaired mitophagy/UPS; somatic PARK2 mutations found in glioblastoma and other cancers acting as tumor suppressor <a href="../results/extraction-result-45.html#e45.0" class="evidence-link">[e45.0]</a> <a href="../results/extraction-result-37.html#e37.1" class="evidence-link">[e37.1]</a> <a href="../results/extraction-result-35.html#e35.1" class="evidence-link">[e35.1]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While proteostasis dysfunction in each disease is known, the explicit framework that proteostasis capacity acts as an inverse disease determinant, supported by system-wide transcriptomic patterns and dual-function genes, represents a novel synthesis with predictive power.</p>            <p><strong>What Already Exists:</strong> Proteostasis decline in neurodegeneration and upregulated protein quality control in cancer are well-documented separately. The UPS and autophagy roles in both disease classes have been studied extensively.</p>            <p><strong>What is Novel:</strong> This statement explicitly posits proteostasis capacity as a bidirectional risk determinant creating inverse susceptibility, integrating transcriptomic evidence of opposite regulation with genetic evidence (PARK2, AT-1) showing how the same molecular systems can produce opposite disease outcomes depending on cell type and context.</p>
        <p><strong>References:</strong> <ul>
    <li>Hipp et al. (2019) The proteostasis network and its decline in ageing [General proteostasis framework]</li>
    <li>Ibáñez et al. (2014) Molecular evidence for inverse comorbidity [Transcriptomic opposite regulation of UPS]</li>
    <li>Veeriah et al. (2010) PARK2 mutations in glioblastoma [Dual role evidence]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Transcriptional Program Opposition</h3>
            <p><strong>Statement:</strong> Genome-wide transcriptional programs show systematic opposite regulation between neurodegenerative diseases and cancers: genes and pathways supporting cellular proliferation, genetic information processing, and metabolic activity are upregulated in cancers but downregulated in neurodegeneration, while genes supporting environmental sensing, organismal systems, and stress responses show the reverse pattern. This transcriptional opposition creates mutually exclusive disease states.</p>
            <p><strong>Domain/Scope:</strong> Applies to transcriptional profiles in disease-affected tissues (brain regions in AD/PD, tumor tissues in cancers). Most robust for comparisons between AD/PD/schizophrenia and lung/colorectal/prostate cancers where meta-analyses have been performed.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some genes show same-direction regulation (APP, CCND1, CCNE1 upregulated in both; PTPA downregulated in both)</li>
                <li>Tissue-specific and treatment-related confounders can affect observed patterns</li>
                <li>One significant same-direction overlap found between colorectal cancer and PD upregulated genes</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Meta-analysis identified 74 genes downregulated in all three CNS disorders and upregulated in all three cancers, enriched for RNA splicing, aminoacyl-tRNA ligases, and metabolism; and 19 genes with opposite pattern including stress-response genes (NFKBIA, CDKN1A, MT2A) <a href="../results/extraction-result-47.html#e47.0" class="evidence-link">[e47.0]</a> <a href="../results/extraction-result-47.html#e47.3" class="evidence-link">[e47.3]</a> </li>
    <li>GSEA identified 30 shared KEGG pathways between CNS disorders and cancers, 80% (24/30) deregulated in opposite directions; metabolism and genetic information processing up in cancers/down in CNS, environmental information processing and organismal systems up in CNS/down in cancers <a href="../results/extraction-result-47.html#e47.0" class="evidence-link">[e47.0]</a> </li>
    <li>Transcriptional regulatory analysis of AD hippocampus vs breast cancer identified 10 of 17 shared transcription factors with opposite activities (AD↑/BC↓ or AD↓/BC↑), regulating immune, apoptosis and DNA-repair pathways <a href="../results/extraction-result-39.html#e39.0" class="evidence-link">[e39.0]</a> </li>
    <li>CircRNA expression analysis shows negative correlation between AD and multiple cancers: 12 of 13 shared circRNAs exhibit inverse expression patterns (AML r=-0.33, p=0.0038; renal cell carcinoma r=-0.34, p=0.0026) <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>PIN1 expression downregulated in AD and PD but upregulated in colorectal cancer; ATP13A2 downregulated in AD/PD but upregulated in lung, colorectal, and prostate cancers <a href="../results/extraction-result-47.html#e47.1" class="evidence-link">[e47.1]</a> <a href="../results/extraction-result-47.html#e47.2" class="evidence-link">[e47.2]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While transcriptomic opposite regulation has been documented, the formalization as a systems-level principle of mutually exclusive transcriptional states with quantified pathway-level patterns and multiple regulatory layers (mRNA, circRNA, TF activity) represents significant novel synthesis.</p>            <p><strong>What Already Exists:</strong> Individual studies have noted opposite expression of specific genes between neurodegeneration and cancer. Transcriptomic analyses identifying sets of oppositely regulated genes have been published (Ibáñez et al. 2014).</p>            <p><strong>What is Novel:</strong> This statement elevates the observation to a systems-level principle: genome-wide transcriptional programs are systematically opposed, creating mutually exclusive cellular states. The integration of mRNA, circRNA, and transcription factor activity data into a unified framework of transcriptional opposition is novel.</p>
        <p><strong>References:</strong> <ul>
    <li>Ibáñez et al. (2014) Molecular evidence for inverse comorbidity [First systematic transcriptomic meta-analysis]</li>
    <li>Jia et al. (2017) Transcriptional regulation differences between AD and breast cancer [TF activity analysis]</li>
    <li>Zhang et al. (2021) CircRNA analysis [Novel regulatory layer]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: Immune-Inflammatory Axis Divergence</h3>
            <p><strong>Statement:</strong> Immune and inflammatory signaling pathways are differentially regulated in neurodegeneration versus cancer, with chronic neuroinflammation (elevated IL-12/IL-23, IL-17, TLR activation, NLRP3 inflammasome) promoting neurodegeneration while similar inflammatory states in tumors can support immune evasion and tumor progression. However, robust anti-tumor immunity (IL-12-mediated) protects against cancer but may exacerbate neuroinflammation. This creates an immune-inflammatory set-point that inversely affects disease risks.</p>
            <p><strong>Domain/Scope:</strong> Applies to immune-competent individuals with age-related neurodegeneration and solid tumors where immune surveillance is relevant. Most applicable to cancers with significant immune microenvironment involvement and neurodegenerative diseases with prominent neuroinflammation (AD, PD).</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Virus-associated liver cancer shows positive correlation with PD, possibly through virus-induced neuroinflammation creating concordant rather than opposing effects</li>
                <li>Immunotherapy effects in cancer patients on neurodegeneration risk are unknown</li>
                <li>Environmental factors (pathogen exposure) can modulate the relationship as shown in AT-1 mutant mice</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>CircRNA-miRNA-mRNA network analysis identified IL-12/IL-23 signaling and viral response pathways as inversely regulated between AD and multiple cancers; IL-12 inhibition in APP/PS1 mice reduced cerebral Aβ <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Transcriptional analysis identified opposite regulation of immune-related transcription factors: HMGB3 (immune nucleic-acid sensing/NF-κB/Irf3 activation) AD↑/BC↓, regulating cytokine signaling (IL-2, IL-6) and TLR4 signaling <a href="../results/extraction-result-39.html#e39.0" class="evidence-link">[e39.0]</a> </li>
    <li>AT-1 S113R heterozygous mice develop neurodegeneration independent of environment, but pathogen exposure induces chronic IL-17/neutrophil-driven inflammation leading to cancer (55.5% cancer incidence in open facility vs 0% in SPF) <a href="../results/extraction-result-150.html#e150.0" class="evidence-link">[e150.0]</a> </li>
    <li>Meta-analysis shows inflammasome/NLRP3 activation contributes to AD pathology in mouse models; Aβ is toxic to NK cells; tumor microenvironments often show immune suppression <a href="../results/extraction-result-38.html#e38.0" class="evidence-link">[e38.0]</a> </li>
    <li>NF-κB pathway activity overlaps in both diseases but with context-dependent outcomes: promotes inflammation in AD while supporting tumor survival/immune evasion in cancer <a href="../results/extraction-result-44.html#e44.3" class="evidence-link">[e44.3]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While inflammation's role in each disease is known, the explicit framework that immune-inflammatory set-points determine inverse risk, with environmental modulation and tissue-context-dependent outcomes, represents a novel mechanistic hypothesis with specific molecular predictions.</p>            <p><strong>What Already Exists:</strong> Neuroinflammation in neurodegeneration and tumor immune microenvironments are extensively studied separately. The role of cytokines and inflammasomes in each disease is well documented.</p>            <p><strong>What is Novel:</strong> This statement proposes that immune-inflammatory set-points create bidirectional disease risk through divergent effects of similar inflammatory states in different tissue contexts, with the environmental modulation (pathogen exposure) and specific molecular mediators (IL-12/IL-23, NLRP3) creating a testable framework.</p>
        <p><strong>References:</strong> <ul>
    <li>Vom Berg et al. (2012) IL-12/IL-23 inhibition reduces Aβ in mice [Immune modulation in AD]</li>
    <li>Grivennikov et al. (2010) Immunity, inflammation, and cancer [Inflammation in tumorigenesis]</li>
    <li>Kaur et al. (2014) AT-1 study [Environmental modulation of inverse relationship]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Individuals with germline variants that moderately increase p53 activity should show reduced cancer incidence but potentially increased risk of age-related neurodegeneration compared to population averages</li>
                <li>Pharmacological mild enhancement of proteasome activity in middle-aged individuals should reduce protein aggregation biomarkers and neurodegenerative risk while potentially increasing proliferative markers and cancer risk, necessitating careful risk-benefit analysis</li>
                <li>Biomarkers of enhanced cellular apoptosis (e.g., elevated apoptotic markers in peripheral blood mononuclear cells) should inversely correlate with cancer incidence but positively correlate with neurodegenerative disease risk in longitudinal cohorts</li>
                <li>Gene expression signatures from peripheral tissues that predict high proteostasis capacity should correlate with reduced neurodegeneration biomarkers but potentially increased proliferative disease markers</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>If PIN1 activity could be precisely titrated systemically (e.g., through small molecule modulators), there may exist an optimal intermediate level that minimizes combined risk of both cancer and neurodegeneration, though this may vary by age, tissue, and genetic background</li>
                <li>Individuals who develop cancer and receive certain chemotherapies or immunotherapies may show altered subsequent risk of neurodegeneration depending on how treatments affect the cell fate rheostat set-points; protective effects of tumor suppressor activation by some treatments versus neurotoxic effects of others may create complex patterns</li>
                <li>Environmental or pharmacological interventions that enhance proteostasis capacity in middle age (before significant neurodegeneration or cancer development) might prevent both diseases if initiated at optimal timing, or might increase cancer risk if the enhancement favors proliferative capacity over protein quality control</li>
                <li>The cell fate rheostat set-points may be partially reversible through interventions targeting epigenetic regulators or master transcription factors, potentially allowing dynamic adjustment of disease risk profiles across lifespan</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If individuals with high p53 activity (measured by validated biomarkers or genetic variants) do not show inverse patterns of cancer versus neurodegeneration risk, this would challenge the cell fate rheostat principle</li>
                <li>If pharmacological enhancement of proteasome activity reduces neurodegeneration risk without affecting cancer risk (or vice versa), this would suggest proteostasis divergence is not a key determinant of inverse susceptibility</li>
                <li>If transcriptional profiles do not show systematic opposite regulation between neurodegeneration and cancer when measured in well-controlled studies accounting for confounders (treatment, tissue, age), the transcriptional opposition principle would be challenged</li>
                <li>If modulation of immune-inflammatory pathways (e.g., IL-12/IL-23 blockade) affects neurodegeneration and cancer risks in the same direction rather than opposite directions, this would contradict the immune axis divergence model</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Melanoma shows positive rather than inverse association with Parkinson's disease across multiple studies; shared biology (alpha-synuclein in melanocytes, CDKN2A locus) may create concordant rather than opposing risks <a href="../results/extraction-result-42.html#e42.3" class="evidence-link">[e42.3]</a> <a href="../results/extraction-result-45.html#e45.3" class="evidence-link">[e45.3]</a> <a href="../results/extraction-result-38.html#e38.1" class="evidence-link">[e38.1]</a> </li>
    <li>Vascular dementia and stroke show increased rather than decreased cancer diagnosis, indicating inverse relationship is specific to protein-aggregation neurodegenerative diseases <a href="../results/extraction-result-36.html#e36.1" class="evidence-link">[e36.1]</a> <a href="../results/extraction-result-38.html#e38.0" class="evidence-link">[e38.0]</a> </li>
    <li>Liver cancer (particularly viral hepatitis-associated) shows positive correlation with PD, potentially due to virus-induced neuroinflammation <a href="../results/extraction-result-32.html#e32.2" class="evidence-link">[e32.2]</a> </li>
    <li>Some genes (APP, CCND1, CCNE1, PTPA) are regulated in the same direction in both cancer and neurodegeneration, showing not all molecular changes follow the inverse pattern <a href="../results/extraction-result-46.html#e46.4" class="evidence-link">[e46.4]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>